TJ108

NSCLC

IND-enablingActive

Key Facts

Indication
NSCLC
Phase
IND-enabling
Status
Active
Company

About Phrontline Biopharma

A Chinese biotech developing innovative bispecific dual-payload ADCs to deliver next-generation frontline cancer therapies.

View full company profile

Therapeutic Areas

Other NSCLC Drugs

DrugCompanyPhase
REQORSAGenprexPhase 1/2
HBM7008Harbour BioMedPhase 1
HBM7004Harbour BioMedDiscovery
LR19125AVEO OncologyPre-clinical
MET FISH CDxAmoy DiagnosticsCommercial